A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya

Trial Profile

A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms PASSOS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 26 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
    • 26 Oct 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
    • 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top